Business
Cardio Diagnostics Holdings Inc Sponsors the Illinois Association of Medicaid Health Plan’s Annual Conference
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring the Illinois Association of Medicaid Health
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring the Illinois Association of Medicaid Health Plans’ (IAMHP) Annual Conference entitled “Bringing Equity into Focus.” The conference is taking place this week, November 14-16, 2022, at the Hyatt Lodge Hotel in Oakbrook. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, PhD, CEO, is presenting on How to Optimize Health Equity Initiatives at the Population Health Level.\n\nIAMPH’s conferences are among the Medicaid industry’s leading events covering provider, payer, and patient-centered concerns for vulnerable populations. This annual meeting brings together key Medicaid stakeholders across Illinois to discuss critical patient, equity, and reimbursement considerations.\n\nAs Dr. Dogan will note in her presentation, “Thinking about health equity, especially in the context of chronic diseases, is critical as undiagnosed and untreated chronic conditions are responsible for high morbidity and costly utilization.”\n\nThe conference’s theme this year is to challenge Medicaid plans, state organizations, and medical technology vendors to optimize and actualize health equity. “So, when we focus on equitable access to care and equitable access to high-quality clinical care, we can actually help drive down the population incidence of chronic conditions and as a result reduce the consumption of healthcare resources while improving health outcomes,” shared Dr. Dogan.\n\nAbout Cardio Diagnostics\n\nCardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.\n\nForward-Looking Statements\n\nThis press release includes \"forward-looking statements\" within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Words such as \"expect,\" \"estimate,\" \"project,\" \"budget...